Proteovant is a biotechnology company that is focused on creating medicines to treat patients with life-altering, debilitating diseases. Their mission is to use the human body's innate cellular machinery to ‘delete’ proteins and unlock the potential of this burgeoning field of science to create more effective, better-targeted medicines. Proteovant has proprietary technologies, business acumen, and risk tolerance to target the ‘undruggable’ and a larger percentage of the proteome. Their team is passionate about uncovering new, previously inaccessible drug targets and delivering next-generation medicines to patients. Proteovant is science-driven, ambitious, collaborative, analytical, resourceful and decisive, and they plan to make a profit by successfully creating medicines to treat patients with life-altering diseases. What makes Proteovant different from other businesses in the same industry is their ability to target the ‘undruggable’ and a larger percentage of the proteome, as well as their team's passion for uncovering new, previously inaccessible drug targets.